Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Celldex Therapeutics buy Guggenheim

Start price
€47.20
27.02.24 / 50%
Target price
€82.92
27.02.25
Performance (%)
-19.07%
Price
€38.20
02.05.24
Summary
This prediction is currently active. The prediction for Celldex Therapeutics disappoints with a performance of -19.07%. This prediction currently runs until 27.02.25. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this prediction
Performance without dividends (%)
Name 1w 1m
Celldex Therapeutics 12.353% 12.353%
iShares Core DAX® -0.922% -1.993%
iShares Nasdaq 100 0.371% -0.868%
iShares Nikkei 225® 2.224% -5.187%
iShares S&P 500 -0.026% -0.918%

Comments by Guggenheim for this prediction

In the thread Celldex Therapeutics diskutieren
Prediction Buy
Perf. (%) -19.07%
Target price 82.917
Change
Ends at 27.02.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat